Acumen Pharmaceuticals(ABOS) - 2024 Q2 - Quarterly Results

Exhibit 99.1 Acumen Pharmaceuticals Reports Second Quarter 2024 Financial Results and Business Highlights • Actively enrolling subjects in ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer's disease • Dosed the first subject in a Phase 1 study to support subcutaneous administration of sabirnetug in July 2024 with topline results anticipated in the first quarter of 2025 • Cash, cash equivalents and marketable securities of $281.4 million as of Jun. 30, 2024, ...